ClinicalTrials.gg
CompletedNCT04131309Updated Nov 12, 2026Results posted

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

A Phase 2 interventional study of Daratumumab and Bortezomib Injection in Light Chain (AL) Amyloidosis, Stage 3B, sponsored by Stichting European Myeloma Network. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Stichting European Myeloma Network · Phase 2, Interventional, and Treatment

How we know

Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Amyloidosis with a site in France — 17 open to participants now, 22 under way, 8 of them phase 3. Amyloidosis · France.

Enrollment
38th of 48
40 · median 145
Started
2019
with 4 others
Phase 2
10 of 56
2 open now
Registered
27th of 56
by date

Among the 56 studies in Amyloidosis with a site in France, this one is the 38th largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2019, is one of 10 in phase 2, and was the 27th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

17 of the 56 studies in Amyloidosis with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyloidosis with a site in France, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.

Read the detailed description

The current study aims to investigate daratumumab as a monotherapy in patients with stage 3B AL amyloidosis who have not received prior therapy. Approximately 40 subjects will receive primary therapy with daratumumab. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up Phase.

A safety run-in will be conducted in 6 subjects treated with daratumumab for at least 1 cycle to establish safety of daratumumab in patients with stage 3B AL amyloidosis. Dosing of these 6 subjects will be staggered so that no subject will receive their first dose sooner than 48 hours after the previously enrolled subject. Safety evaluation will be performed by a Data Safety Monitoring Board (DSMB) after at least 1 cycle is completed for all 6 subjects. If no safety signal is observed, the enrollment of the rest of the patients will begin.

In Protocol Version 1.0, subjects receive daratumumab IV at a dose of 16 mg/kg. As of Protocol Amendment 1, all new subjects are dosed subcutaneously with daratumumab co-formulated with recombinant human hyaluronidase rHuPH20 (daratumumab SC). Subjects who already began treatment with daratumumab IV (i.e., prior to Amendment 1) switch to daratumumab SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.

Subjects who will not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib (1.3 mg/m2 weekly for a maximum of 6 cycles) and low dose dexamethasone (total maximum weekly dose of 20mg).

03

Conditions studied

  • Light Chain (AL) Amyloidosis, Stage 3B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • KEY INCLUSION CRITERIA

    1. Men or women 18 years of age or older.
    2. Diagnosis of amyloidosis, AL type, based on:

      1. Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in Congo Red stained tissue specimens (excluding bone marrow) or characteristic electron microscopy appearance

        Considerations for specific populations where other types of amyloidosis may be encountered:

        • For male subjects over 70 years of age who have cardiac involvement only, and subjects of African descent (black subjects), mass spectrometry, immunoelectron microscopy, or other immunohistochemistry-based typing of AL amyloid in a tissue or a negative bone scintigraphy with Tc99m-PYP or -DPD is recommended to rule out other types of amyloidosis such as age related amyloidosis and/or hereditary amyloidosis (ATTR mutation) AND
      2. of amyloid light chain amyloidosis as defined by at least ONE of the following:

        • serum monoclonal protein ≥0.5 g/dL by protein electrophoresis (routine serum protein electrophoresis and immunofixation performed at local lab),
        • serum free light chain (FLC) ≥2.0 mg/dL (20 mg/L) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved free light chains (dFLC) ≥2mg/dL (20 mg/L). Serum free light chains (FLCs) will be measured using the Freelite assay at a central laboratory
        • Note: Measurable disease by Urine Bence-Jones Proteinuria is not sufficient for study enrolment.

        AND

      3. Cardiac involvement by AL amyloidosis according to consensus guidelines
    3. Mayo Stage 3B disease, defined as both A. increased cardiac troponin (hsTnT > 54 pg/ml) AND B. increased NT-proBNP ≥ 8500 pg/ml
    4. For subjects with congestive heart failure, symptoms should be optimally managed and clinically stable with no cardiovascular-related hospitalizations within 2 weeks prior to Cycle 1 Day 1, as assessed by the Principal Investigator. [See also exclusion criteria 3]
    5. (ECOG) Performance Status (PS) 0, 1, 2 or 3
    6. Subject must have pre-treatment clinical laboratory values meeting the following criteria during the Screening Phase:

      1. ≥1.0 × 109/L;
      2. level ≥8.0 g/dL (≥5 mmol/L)
      3. count ≥75 × 109/L; platelet transfusions are NOT acceptable
      4. level (ALT) ≤2.5 x the (ULN);
      5. Aspartate aminotransferase (AST) ≤2.5 x ULN
      6. Total level ≤1.5 × ULN, except for subjects with history of Gilbert Syndrome, in which case direct bilirubin ≤ 2 × ULN
      7. Estimated (eGFR) ≥20 mL/min; Please note that the eGFR is measured using the CKD-EPI equation
    7. Women of must commit to either abstain continuously from heterosexual sexual intercourse (if this is the preferred and usual lifestyle of the subject) or to use 2 methods of reliable simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin prior to dosing and continue for 1 year after discontinuation of cyclophosphamide or 3 months after discontinuation of daratumumab, whichever is longer. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy.
    8. During the study and for 3 months after receiving the last dose of daratumumab, female subjects must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction.
    9. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g. either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository during and up to 3 months after discontinuation of daratumumab. All men must not donate sperm during the study and for 3 months after discontinuation of daratumumab.
    10. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to Cycle 1 Day 1. For requirements during the Treatment Phase, please see the Time and Events Schedule.
    11. Each subject must sign an form (ICF) indicating that he or she understands the purpose of the procedures required for the study and are willing to participate in the study. Subjects must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, as referenced in the ICF.

Exclusion criteria

Exclusion Criteria:

Any potential subject who meets any of the following criteria will be excluded from participating in the study:

  1. Prior therapy for AL amyloidosis or multiple myeloma with the exception of 160 mg dexamethasone (or equivalent ) prior to Cycle 1 Day 1
  2. Previous or current diagnosis of symptomatic multiple myeloma including the presence of lytic bone disease, plasmacytomas, ≥ 60% plasma cells in the bone marrow, and/or hypercalcemia.
  3. Evidence of significant cardiovascular conditions as specified below:

    1. (NYHA) classification of heart failure, stages IIIB or IV
    2. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (eg prior myocardial infarction with documented history of cardiac enzyme elevation and (ECG) changes) or uncorrected valvular disease, and not due to AL amyloid cardiomyopathy
    3. Hospitalization for unstable angina or myocardial infarction, or percutaneous cardiac intervention with recent stent, or coronary artery bypass grafting, all within 6 months prior to first dose
    4. Subjects with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/ICD is indicated but will not be placed (subjects who do have a pacemaker/ ICD are allowed in the study)
    5. Screening 12-lead ECG showing a baseline as corrected by Fridericia's formula (QTcF) >500 msec. Subjects who have pacemaker may be included regardless of calculated QTc interval.
    6. Supine systolic blood pressure \<90 mmHg, or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of >20 mmHg despite medical management (e.g. midodrine, fludrocortisones) in the absence of volume depletion
  4. Subjects planning to undergo a stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted
  5. Diagnosed or treated for other than AL, except:

    1. Malignancy treated with curative intent and with no known active disease present for ≥24 months before Cycle 1 Day 1
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated carcinoma in situ (e.g. cervical, breast) with no evidence of disease
  6. Subject has known (COPD) with a (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal.
  7. Subject has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
  8. Subject is known to be seropositive for (HIV). HIV positive subjects who are stable on highly active antiretroviral therapy (HAART) with no opportunistic infections within the last 6 months are eligible.
  9. Subjects known to be:

    1. Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [antiHBc] and/or antibodies to hepatitis B surface antigen [antiHBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (antiHBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
    2. Seropositive for (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).
  10. Subject has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
  11. Any form of non-AL amyloidosis including, wild type or mutated (ATTR) amyloidosis.
  12. Subject has known allergies, or intolerance to monoclonal antibodies or human proteins, or their (refer to Investigator Brochure), or known sensitivity to mammalian-derived products.
  13. Subject is known or suspected of not being able to comply with the study protocol (eg, because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise their well-being) or that could prevent, limit or confound the protocol-specified assessments.
  14. Subject is a female who is pregnant or breast-feeding or planning to become pregnant while enrolled in this study or within 3 months following discontinuation of daratumumab.
  15. Subject has received an drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks prior to Cycle 1, Day 1.
  16. Subject has had major surgery within 2 weeks prior to Cycle 1, Day 1, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration. Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Daratumumab

    Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter. Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone.

    Drug: Daratumumab · Drug: Bortezomib Injection · Drug: Dexamethasone oral tablet

Interventions

  • As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.

  • DrugBortezomibStudies of BortezomibBortezomib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection

    Also known as: velcade

  • DrugDexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    percentage of participants

    Time frame: 6 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    Best hematologic response rates, per International Amyloidosis Consensus Criteria: CR Normalization of free light chain ratio, negative serum and urine immunofixation; VGPR with baseline dFLC ≥ 50 mg/L, reduction in the dFLC to \<40 mg/L; PR b. baseline dFLC ≥ 50 mg/L, reduction in dFLC by ≥ 50% c. A greater than 50% reduction in M protein concentration, baseline dFLC is \<50 mg/L, M protein (≥5 g/L) d. baseline dFLC ≥ 20 and \< 50 mg/dL: dFLC \< 10 mg/dL; No response, Less than a PR;

    Time frame: Overall (up to 9 months), 3 and 6 months

  2. Major Organ Deterioration Progression-Free Survival (MOD-PFS).

    Major Organ Deterioration Progression-Free Survival (MOD-PFS) is a composite endpoint of clinically observable endpoints and will be defined from the start of study treatment (Cycle 1 Day 1) to any one of the following events (whichever occurs first) • Death or Major organ deterioration

    Time frame: Overall up to death or major organ deterioration

  3. Progression Free Survival

    documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression/need for transplant, or need for additional therapy (excluding the addition of bortezomib under protocol) or death due to any cause, whichever occurs first according to central laboratory results and judged by international consensus guidelines

    Time frame: Overall up to 2 years

  4. Time to Hematologic Response

    to evaluate the time to hematologic response

    Time frame: overall up to 2 years

  5. Proportion of Additional Treatment

    The proportion of subjects who received additional treatment with bortezomib and low dose dexamethasone (at the investigator's discretion).

    Time frame: every 28 days, from start of study treatment (cycle 1 Day1) until end of treatment with a maximum of 2 years, average of 6 months

  6. Organ Response Rate (OrRR) Heart

    the organ response rate for the heart

    Time frame: at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months (maximum of 2 years)

  7. EORTC QLQ-C30 Scores Will be Summarized at Each Time Point.

    The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

    Time frame: Score changes from baseline to 4 months

  8. Organ Response Rate (OrRR) Kidney

    the organ response rate for kidney involvement

    Time frame: from registration to the date of disease progression or death with a maximum of 2 years

  9. Organ Response Rate (OrRR) Liver

    the organ response rate for liver involvement

    Time frame: from registration to the date of disease progression or death with a maximum of 2 years

  10. EORTC QLQ-C30 Scores to End of Treatment

    The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

    Time frame: Score changes from baseline to end of treatment (EOT)

07

Results

Posted Nov 12, 2026
Limitations and caveats
The trial has certain limitations inherent to the studied patient population. First, the trial was not powered to assess the hematological and organ responses, as well as the quality-of-life outcomes. Second, as AL amyloidosis is a rare disease, the patient selection bias cannot be excluded as the included patients had to be able to travel to the participating reference centers. The characteristics of these patients, however, indicate a very sick population with very advanced cardiac dysfunction

Participant flow

Forty patients were included between 23 September 2019 and 12 January 2023.

Participant flow — Overall Study
MilestoneDaratumumab
Started40
Completed13
Not completed27
Withdrew: Adverse event3
Withdrew: Death14
Withdrew: Physician decision2
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy7

Outcome measures

PrimaryOverall Survival

percentage of participants

Time frame:
6 months
Reported as:
Number · Percentage of participants alive at 6 mo
Overall Survival
Percentage of participants alive at 6 moDaratumumab
Overall Survival65.0 (51.0 to 76.0)
SecondaryOverall Response Rate (ORR)

Best hematologic response rates, per International Amyloidosis Consensus Criteria: CR Normalization of free light chain ratio, negative serum and urine immunofixation; VGPR with baseline dFLC ≥ 50 mg/L, reduction in the dFLC to \<40 mg/L; PR b. baseline dFLC ≥ 50 mg/L, reduction in dFLC by ≥ 50% c. A greater than 50% reduction in M protein concentration, baseline dFLC is \<50 mg/L, M protein (≥5 g/L) d. baseline dFLC ≥ 20 and \< 50 mg/dL: dFLC \< 10 mg/dL; No response, Less than a PR;

Time frame:
Overall (up to 9 months), 3 and 6 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsDaratumumab
Overall — VGPR10
Overall — CR11
Overall — PR9
Overall — No response7
Overall — Death before 2 efficacy assessments3
3 months — VGPR13
3 months — CR2
3 months — PR13
3 months — No response9
3 months — Death before 2 efficacy assessments3
6 months — VGPR14
6 months — CR5
6 months — PR11
6 months — No response7
6 months — Death before 2 efficacy assessments3
SecondaryMajor Organ Deterioration Progression-Free Survival (MOD-PFS).

Major Organ Deterioration Progression-Free Survival (MOD-PFS) is a composite endpoint of clinically observable endpoints and will be defined from the start of study treatment (Cycle 1 Day 1) to any one of the following events (whichever occurs first) • Death or Major organ deterioration

Time frame:
Overall up to death or major organ deterioration
Reported as:
Median · months
Major Organ Deterioration Progression-Free Survival (MOD-PFS).
monthsDaratumumab
Major Organ Deterioration Progression-Free Survival (MOD-PFS).9.46 (2.79 to 26.97)
SecondaryProgression Free Survival

documentation of hematologic disease progression, or organ (cardiac, renal, or liver) progression/need for transplant, or need for additional therapy (excluding the addition of bortezomib under protocol) or death due to any cause, whichever occurs first according to central laboratory results and judged by international consensus guidelines

Time frame:
Overall up to 2 years
Reported as:
Median · months
Progression Free Survival
monthsDaratumumab
Progression Free Survival8.46 (2.79 to 18.50)
SecondaryTime to Hematologic Response

to evaluate the time to hematologic response

Time frame:
overall up to 2 years
Reported as:
Median · months
Time to Hematologic Response
monthsDaratumumab
Time to Hematologic Response0.23 (0.23 to 0.92)
SecondaryProportion of Additional Treatment

The proportion of subjects who received additional treatment with bortezomib and low dose dexamethasone (at the investigator's discretion).

Time frame:
every 28 days, from start of study treatment (cycle 1 Day1) until end of treatment with a maximum of 2 years, average of 6 months
Reported as:
Count of participants · Participants
Proportion of Additional Treatment
ParticipantsDaratumumab
Patients who received ≥1 bortezomib dose in addition to daratumumab10
Patients with ≥1 low dose dexamethasone administration9
SecondaryOrgan Response Rate (OrRR) Heart

the organ response rate for the heart

Time frame:
at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months (maximum of 2 years)
Reported as:
Count of participants · Participants
Organ Response Rate (OrRR) Heart
ParticipantsDaratumumab
3 months — Response9
3 months — No response7
3 months — Progression8
3 months — Treatment discontinuation before the cutoff point15
3 months — Not evaluated1
6 months — Response12
6 months — No response4
6 months — Progression7
6 months — Treatment discontinuation before the cutoff point17
6 months — Not evaluated0
9 months — Response12
9 months — No response3
9 months — Progression4
9 months — Treatment discontinuation before the cutoff point20
9 months — Not evaluated1
12 months — Response15
12 months — No response1
12 months — Progression1
12 months — Treatment discontinuation before the cutoff point23
12 months — Not evaluated0
18 months — Response13
18 months — No response0
18 months — Progression1
18 months — Treatment discontinuation before the cutoff point25
18 months — Not evaluated1
24 months — Response11
24 months — No response2
24 months — Progression0
24 months — Treatment discontinuation before the cutoff point27
24 months — Not evaluated0
SecondaryEORTC QLQ-C30 Scores Will be Summarized at Each Time Point.

The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

Time frame:
Score changes from baseline to 4 months
Reported as:
Mean · score on a scale
EORTC QLQ-C30 Scores Will be Summarized at Each Time Point.
score on a scaleDaratumumab
summary score1.8 ± 20.1
Physical functioning-1.4 ± 25.3
Role functioning0.7 ± 38.8
Emotional functioning3.2 ± 15.9
Cognitive functioning4.5 ± 11.7
Social functioning0.8 ± 40.6
Global health status/QoL0.4 ± 12.5
Fatigue2.3 ± 34.6
Nausea / vomiting-5.6 ± 16.9
Pain6.5 ± 30.9
Dyspnea-11.1 ± 37.0
Insomnia-9.1 ± 35.9
Appetite loss-7.6 ± 34.0
Constipation12.1 ± 26.3
Diarrhea-7.6 ± 20.4
Financial problems-1.5 ± 12.5
SecondaryOrgan Response Rate (OrRR) Kidney

the organ response rate for kidney involvement

Time frame:
from registration to the date of disease progression or death with a maximum of 2 years
Reported as:
Count of participants · Participants
Organ Response Rate (OrRR) Kidney
ParticipantsDaratumumab
3 months — Response1
3 months — No response8
3 months — Progression2
3 months — Treatment discontinuation before the cutoff point8
3 months — Not evaluated1
6 months — Response3
6 months — No response5
6 months — Progression3
6 months — Treatment discontinuation before the cutoff point9
6 months — Not evaluated0
9 months — Response3
9 months — No response6
9 months — Progression1
9 months — Treatment discontinuation before the cutoff point10
9 months — Not evaluated0
12 months — Response4
12 months — No response4
12 months — Progression2
12 months — Treatment discontinuation before the cutoff point10
12 months — Not evaluated0
18 months — Response6
18 months — No response1
18 months — Progression1
18 months — Treatment discontinuation before the cutoff point11
18 months — Not evaluated1
24 months — Response3
24 months — No response3
24 months — Progression2
24 months — Treatment discontinuation before the cutoff point12
24 months — Not evaluated0
SecondaryOrgan Response Rate (OrRR) Liver

the organ response rate for liver involvement

Time frame:
from registration to the date of disease progression or death with a maximum of 2 years
Reported as:
Count of participants · Participants
Organ Response Rate (OrRR) Liver
ParticipantsDaratumumab
3 months — No response4
3 months — Treatment discontinuation before the cutoff point1
6 months — No response4
6 months — Treatment discontinuation before the cutoff point1
9 months — No response3
9 months — Treatment discontinuation before the cutoff point2
12 months — No response2
12 months — Treatment discontinuation before the cutoff point3
18 months — No response2
18 months — Treatment discontinuation before the cutoff point3
24 months — No response1
24 months — Treatment discontinuation before the cutoff point4
SecondaryEORTC QLQ-C30 Scores to End of Treatment

The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.

Time frame:
Score changes from baseline to end of treatment (EOT)
Reported as:
Mean · score on a scale
EORTC QLQ-C30 Scores to End of Treatment
score on a scaleDaratumumab
summary score1.7 ± 20.1
Physical functioning-0.4 ± 31.2
Role functioning7.6 ± 41.1
Emotional functioning-0.1 ± 16.9
Cognitive functioning-2.5 ± 16.0
Social functioning-1.5 ± 41.1
Global health status/QoL2.9 ± 23.3
Fatigue-0.8 ± 36.5
Nausea / vomiting-5.1 ± 19.3
Pain6.2 ± 28.3
Dyspnea-6.9 ± 38.3
Insomnia-8.8 ± 33.1
Appetite loss-3.9 ± 30.4
Constipation-2.0 ± 16.3
Diarrhea-4.9 ± 21.9
Financial problems-1.0 ± 15.3

Adverse events

Collected over from signing of the informed Consent Form until 30 days after the last dose of study treatment, up to 25 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab20/40 (50%)31/40 (77.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventDaratumumab
Cardiac failureCardiac disorders7/40
hematologic progressionBlood and lymphatic system disorders5/40
sudden cardiac deathCardiac disorders4/40
Cardiac failure congestiveCardiac disorders3/40
Acute kidney injuryRenal and urinary disorders3/40
COVID-19Infections and infestations2/40
SepsisInfections and infestations2/40
Septic ShockInfections and infestations2/40
Atrial fibrillationCardiac disorders1/40
Atrial thrombosisCardiac disorders1/40
Most frequent other events
Showing 10 of 153
Most frequent other events
EventDaratumumab
Edema peripheralGeneral disorders17/40
ConstipationGastrointestinal disorders13/40
Orthostatic hypotensionVascular disorders11/40
FatigueGeneral disorders9/40
Cardiac failureCardiac disorders8/40
DyspneaCardiac disorders7/40
Eastern Cooperative Oncology Group performance status worsenedInvestigations7/40
HypokalemiaMetabolism and nutrition disorders7/40
AnemiaBlood and lymphatic system disorders6/40
NauseaGastrointestinal disorders6/40

Baseline characteristics

Age, Customized
Age, Customized(years)Daratumumab
Age in years70.1 ± 10.1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daratumumab
Race — White36
Race — Not reported4
organ involvement apart from the heart
organ involvement apart from the heart(Participants)Daratumumab
No7
Yes33
Age, Customized
Age, Customized(Participants)Daratumumab
<75 years26
≥75 years14
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab
Female18
Male22
ECOG
ECOG(Participants)Daratumumab
1= Symptoms, but nearly ambulatory16
2= Some bedtime, but to be in bed <50% of normal daytime21
3= Needs to be in bed >50% of normal daytime3
NYHA classification
NYHA classification(Participants)Daratumumab
II20
IIIA19
IIIB1
08

Study locations

5 sites
  • Hopitaux Universitaires Henri-Mondor
    Créteil, France
  • Hopital De Rangueil CHU
    Toulouse, France
  • National and Kapodistrian University of Athens, School of Medicine
    Athens, Greece
  • University Hospital San Matteo
    Pavia, Italy
  • UMCU
    Utrecht, Netherlands
09

References and documents

Publications

  • Kastritis E, Minnema MC, Dimopoulos MA, Merlini G, Theodorakakou F, Fotiou D, Huart A, Psarros G, Vassalou H, Sonneveld P, Palladini G. A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis. Blood. 2026 Jun 15:blood.2025032897. doi: 10.1182/blood.2025032897. Online ahead of print. PubMed 42296025 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2025, 64 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 18, 2019
StartActual
Sep 23, 2019
Primary completionActual
Jan 27, 2025
CompletionActual
Jan 27, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedoverall survivalOverall SurvivalTime frame: 6 months
Nov 12, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42296025 ↗
Nov 12, 2026
Secondary outcomes
5 edited, 2 time frame changed, 3 added
What changed in the outcomes
  • EditedoverallOverall Response Rate (ORR)Time frame: at 3 and 6 months → Overall (up to 9 months), 3 and 6 months
  • Editedorgan response rateOrgan Response Rate (OrRR) HeartTime frame: from registration to the date of disease progression or death with a maximum of 2 years → at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months (maximum of 2 years)
  • EditedTime to hematologic responseHematologic ResponseTime frame: 2 years → overall up to 2 years
  • EditedproportionProportion of additional treatmentAdditional TreatmentTime frame: every 28 days, from start of study treatment (cycle 1 Day1) until end of treatment with a maximum of 2 years, average of 6 months
  • ChangedBefore EORTC QLQ-C30 scores will be summarized at each time point. The relationship between response and change in domain scores will be explored. the results will also be presented in two groups (SC and IV daratumumab administration).Now EORTC QLQ-C30 Scores Will be Summarized at Each Time Point.Time frame: on day 1 of cycle 1-6 (each cycle is 28 days), every 8 weeks thereafter until end of treatment with a maximum of 2 years → Score changes from baseline to 4 months
  • AddedOrgan Response Rate (OrRR) KidneyTime frame: from registration to the date of disease progression or death with a maximum of 2 years
  • AddedOrgan Response Rate (OrRR) LiverTime frame: from registration to the date of disease progression or death with a maximum of 2 years
  • AddedEORTC QLQ-C30 Scores to End of TreatmentTime frame: Score changes from baseline to end of treatment (EOT)
  • Time frameMajor Organ Deterioration Progression-Free Survival (MOD-PFS).every 28 days from start of study treatment (cycle 1 Day1) to death or major organ deterioration 2 years with an average of 6 month → Overall up to death or major organ deterioration
  • Time frameProgression Free Survivalfrom registration to the date of disease progression or death with a maximum of 2 years → Overall up to 2 years
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42296025 ↗
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedoverall survivalOverall SurvivalTime frame: 6 months
    Secondary outcomes 5 edited, 2 time frame changed, 3 added
    What changed in the outcomes
    • EditedoverallOverall Response Rate (ORR)Time frame: at 3 and 6 months → Overall (up to 9 months), 3 and 6 months
    • Editedorgan response rateOrgan Response Rate (OrRR) HeartTime frame: from registration to the date of disease progression or death with a maximum of 2 years → at 3 months, 6 months, 9 months, 12 months, 18 months, 24 months (maximum of 2 years)
    • EditedTime to hematologic responseHematologic ResponseTime frame: 2 years → overall up to 2 years
    • EditedproportionProportion of additional treatmentAdditional TreatmentTime frame: every 28 days, from start of study treatment (cycle 1 Day1) until end of treatment with a maximum of 2 years, average of 6 months
    • ChangedBefore EORTC QLQ-C30 scores will be summarized at each time point. The relationship between response and change in domain scores will be explored. the results will also be presented in two groups (SC and IV daratumumab administration).Now EORTC QLQ-C30 Scores Will be Summarized at Each Time Point.Time frame: on day 1 of cycle 1-6 (each cycle is 28 days), every 8 weeks thereafter until end of treatment with a maximum of 2 years → Score changes from baseline to 4 months
    • AddedOrgan Response Rate (OrRR) KidneyTime frame: from registration to the date of disease progression or death with a maximum of 2 years
    • AddedOrgan Response Rate (OrRR) LiverTime frame: from registration to the date of disease progression or death with a maximum of 2 years
    • AddedEORTC QLQ-C30 Scores to End of TreatmentTime frame: Score changes from baseline to end of treatment (EOT)
    • Time frameMajor Organ Deterioration Progression-Free Survival (MOD-PFS).every 28 days from start of study treatment (cycle 1 Day1) to death or major organ deterioration 2 years with an average of 6 month → Overall up to death or major organ deterioration
    • Time frameProgression Free Survivalfrom registration to the date of disease progression or death with a maximum of 2 years → Overall up to 2 years
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04131309
Lead sponsor
Stichting European Myeloma Network
Responsible party
Sponsor
First posted
Oct 18, 2019
Start date
Sep 23, 2019
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion